Diabetic Nephropathy

Researchers Study the Potential Impact of Dapagliflozin on Diabetic Kidney Disease

Publish Date August 27, 2021

A large multinational study examined the potential impact of dapagliflozin on kidney disease in people with type 2 diabetes.

Finerenone Provides CV, Renal Benefits in Diabetes Across CKD Spectrum

Publish Date September 2, 2021

In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.

Frailty Ups Risk for Urinary Tract Infections in Patients With Diabetes, CKD

Publish Date August 10, 2021

More severe frailty predicted a higher risk of UTIs.

Free Fatty Acids Associated With Rapid Decline in Glomerular Filtration Rates in Type 1 Diabetes

Publish Date August 2, 2021

Researchers identified lipidomic predictors of rapid decline of kidney function in individuals with type 1 diabetes.

Dapagliflozin Safe, Effective in Advanced Chronic Kidney Disease

Publish Date July 22, 2021

Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.

High iPTH Linked With Cardiovascular Outcomes in Diabetic Kidney Disease

Publish Date July 21, 2021

Study findings indicate a correlation between iPTH and vascular calcification in patients with diabetic kidney disease.

Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease

Publish Date July 14, 2021

The approval was based on data from the phase 3 FIDELIO-DKD trial.

Efpeglenatide Improves Renal, Cardiovascular Outcomes in High-Risk Diabetes

Publish Date July 1, 2021

Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.

Four in 10 Diabetes Patients Have Kidney Disease

Publish Date June 28, 2021

More than one-quarter are classified as rapid decliners, which was more common with type 2 diabetes

Finerenone Reduces New-Onset AF in Patients With CKD and T2D

Publish Date June 18, 2021

Because finerenone inhibits cardiac remodeling in preclinical models, investigators sought to examine its effect on new-onset AFF by analyzing data from the FIDELIO-DKD phase 3 trial.